Merck & Co., Inc. (MRK): Is This Healthcare Stock A Good Buy?
We recently compiled a list of the . In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other healthcare stocks.
Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, and ability to provide steady income through dividends. This sector encompasses pharmaceutical companies, healthcare providers, biotechnology firms, and medical device manufacturers, all of which are positioned to benefit from enduring trends like aging populations and advancements in medical technology. One of the most compelling reasons to include health stocks in a retirement portfolio is their defensive nature. Health care is a necessity, not a luxury, meaning demand for medical products and services remains steady, even during economic downturns. According to a report by Morningstar, the healthcare sector outperformed the broader market in 75% of US recessions over the past 50 years, demonstrating its ability to provide stability when other sectors falter.
Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs.
Global demographic trends also favor health stocks. The United Nations projects that the number of people aged 65 and older will double by 2050, reaching 1.5 billion. This aging population will drive increased demand for chronic disease management, prescription medications, and long-term care services. The US alone spends over $4.3 trillion annually on health care, according to the Centers for Medicare & Medicaid Services, accounting for nearly 20% of GDP. This figure is expected to rise to $6.8 trillion by 2030, driven by advances in medical technology and higher spending on aging-related health issues. Health stocks, particularly those of established pharmaceutical companies, often provide attractive dividend yields, making them ideal for income-focused retirees.
Drug giants are known for consistently paying and increasing dividends. Dividends provide retirees with regular income, reducing the need to sell assets during market downturns. The healthcare sector is also at the forefront of technological innovation, offering exposure to high-growth areas such as biotechnology, precision medicine, and artificial intelligence in healthcare. Healthcare stocks provide diversification in a retirement portfolio as well, balancing out more volatile sectors like technology or energy. Additionally, healthcare ETFs like the Health Care Select Sector SPDR Fund offer exposure to a wide range of companies, spreading risk while capturing growth potential. For example, Health Care Select Sector SPDR Fund has delivered a 10-year annualized return of 13.4%, outperforming many other sectors.
Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities.
For this article, we selected health stocks that have solid businesses with recurring revenue streams, reliable dividend payouts, and burgeoning growth pipelines. These stocks are also popular among hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ().
A close-up of a person's hand holding a bottle of pharmaceuticals.
Number of Hedge Fund Holders: 86
Merck & Co., Inc. (NYSE:MRK) operates as a healthcare company worldwide. There are several aspects that make this company an attractive investment choice. Merck & Co. (NYSE:MRK) has achieved 14 consecutive years of dividend growth, surpassing the sector median of 2 years by 600%. Secondly, the company has also maintained 35 consecutive years of dividend payments, outperforming the sector median of 15 years by 133.33%. This shows the company's ability to generate profit and provide value to its shareholders, which are indicators of strong financial growth. Moreover, Merck & Co. (NYSE:MRK) has also announced a $17 million commitment over five years (2025-2030) to advance equitable access to culturally responsive care for people with heart conditions in the US communities.
Overall MRK ranks 3rd on our list of the healthcare stocks to buy. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss. Novo Nordisk A/S's (NYSE:NVO) semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used for diabetes and obesity (Ozempic, Rybelsus, and Wegovy). After reviewing all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials, post-marketing surveillance and the medical literature, the committee on Friday concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine. This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment; one person-year corresponds to one person taking semaglutide for one year. Data from clinical trials also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment). Therefore, EMA has recommended that the product information for semaglutide medicines be updated to include NAION as a side effect with a frequency of 'very rare.' In December, a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). Additionally, New research suggests that GLP-1 receptor agonists, widely prescribed for diabetes and weight loss, may significantly raise the risk of age-related macular degeneration in older diabetic patients. A study published on Thursday in JAMA Ophthalmology by the University of Toronto researchers warns of a potential downside: increased risk of neovascular age-related macular degeneration (nAMD) in diabetic users. nAMD is a severe form of age-related macular degeneration characterized by the growth of abnormal blood vessels in the back of the eye. Analyzing medical data from over 1 million Ontario residents with diabetes, researchers identified 46,334 patients prescribed GLP-1 RAs, most of whom were taking semaglutide—likely Ozempic, since Wegovy was only recently approved in Canada. Patients on these medications were matched with participants not on GLP-1 RAs, sharing similar demographics and health profiles, and tracked for three years. The study found that diabetic patients taking GLP-1 RAs for at least six months had double the risk of developing neovascular AMD compared to non-users. Over a mean follow-up period of 2.4 years, 0.2% of the GLP-1 RA cohort progressed to nAMD compared with only 0.1% of control participants, resulting in an increased hazard for nAMD of 2.21 for the GLP-1 RA cohort. The risk was also highest in those with the longest duration of exposure. The Guardian report added that those on the medications for more than 30 months had over three times the risk. The risk was even greater in older patients and those with a prior stroke. Recent findings from the 2025 American Clinical Society of Oncology annual conference suggested that patients using weight loss drugs, including Ozempic, were about 33% more likely to be diagnosed with kidney cancer compared to matched individuals not using the medication. Price Action: NVO stock is up 2.45% at $74.43 at the last check Friday. Read Next:Photo by Tobias Arhelger via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
3 hours ago
- Yahoo
CVS Health Corporation (CVS): Jim Cramer Says You Don't Want Them Buying The Wrong Robots
We recently published a list of . In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer discusses. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The firm's shares have gained 44% year-to-date due to weakness at the firm's primary rival Walgreens. Cramer's previous remarks about CVS Health Corporation (NYSE:CVS) have praised the firm's CEO and his turnaround efforts. The shares gained 4% in May after the firm raised its 2025 profit forecast to a midpoint of $6.10 per share from an earlier $5.87 per share. CVS Health Corporation (NYSE:CVS)'s turnaround efforts which have seen the firm appoint a new CEO and exit its Obamacare direct sales business have contributed to the strong 2025 share price performance. In his recent comments about CVS Health Corporation (NYSE:CVS), Cramer wondered what would happen if the firm automated its pharmacies through robots: 'I mean one of the things that is really meant to be changing here is healthcare. And you don't want, uh, CVS, for instance, if they were to buy a robot, you don't want them saying, do remember that scene, It's a Wonderful Life, where the pharmacist gave them the wrong prescription? You don't want that. You don't want It's a Wonderful Life, to be your life.' In his previous comments, the CNBC host praised the firm's management. Here's what he said: 'Now we've got some healthcare, some issues to talk about on Thursday, that's right, and these are anything but common steady healthcare companies…. There's CVS, which is under new management, put up some really good numbers, and it's just, that's in health insurance, but also it's core drugstore business, which they've closed, all the under performers… As for CVS, the health insurers have taken it on the chin of late. UnitedHealth and Centene both missed expectations. I bet Aetna sticks it.' A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. Overall, CVS ranks 11th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at .